Large-scale testing (Phase 3)Active Not RecruitingNCT05687266
What this trial is testing
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Who this might be right for
NSCLC
AstraZeneca 1,350